Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses
暂无分享,去创建一个
O. Clément | A. Nederveen | A. Radbruch | C. Mallio | C. Quattrocchi | E. Gianolio | I. Dekkers | J. Ramalho | M. Ramalho | Gerard J. Stroomberg | A. J. van der Molen | M. Parillo | A. Rovira | U. Karst
[1] G. Marfia,et al. Skin Thickening of the Scalp and High Signal Intensity of Dentate Nucleus in Multiple Sclerosis , 2022, Investigative radiology.
[2] R. Semelka,et al. Commentary on the Association of Symptoms Associated With Gadolinium Exposure/Gadolinium Deposition Disease and Gadolinium-Based Contrast Agents. , 2022, Investigative radiology.
[3] D. B. Jackson,et al. Gadolinium Deposition Disease: A Case Report and the Prevalence of Enhanced MRI Procedures Within the Veterans Health Administration. , 2022, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.
[4] E. Lancelot,et al. Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure , 2022, Investigative radiology.
[5] A. Al-Muhanna. Gadolinium Retention after Contrast-Enhanced Magnetic Resonance Imaging: A Narratative Review , 2022, Saudi journal of medicine & medical sciences.
[6] J. Weinreb,et al. Symptoms Associated with Gadolinium Exposure (SAGE): A Suggested Term. , 2021, Radiology.
[7] A. Radbruch,et al. Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents. , 2021, Radiology.
[8] Swati Rane Levendovszky,et al. Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate. , 2021, Radiology.
[9] M. Kirchin,et al. Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats , 2021, Journal of magnetic resonance imaging : JMRI.
[10] D. Fine,et al. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. , 2020, Radiology.
[11] M. Fakhoury,et al. Gadolinium Retention in the Central and Peripheral Nervous System: Implications for Pain, Cognition, and Neurogenesis. , 2020, Radiology.
[12] H. Schlemmer,et al. Is Small Fiber Neuropathy Induced by Gadolinium-Based Contrast Agents? , 2020, Investigative radiology.
[13] C. Simpson,et al. Human Hair as a Possible Surrogate Marker of Retained Tissue Gadolinium , 2020, Investigative radiology.
[14] P. Parizel,et al. Gadolinium Deposition Safety: Seeking the Patient’s Perspective , 2020, American Journal of Neuroradiology.
[15] P. Parizel,et al. Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies , 2020, Neuroradiology.
[16] P. Parizel,et al. Within-network brain connectivity in Crohn’s disease patients with gadolinium deposition in the cerebellum , 2020, Neuroradiology.
[17] M. Kirchin,et al. Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats , 2020, Insights into Imaging.
[18] J. Weinreb,et al. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.
[19] M. Sapienza,et al. A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study , 2019, Investigative radiology.
[20] D. Miller,et al. Image Gallery: A case of gadolinium‐associated plaques requiring confirmation with mass spectrometry , 2019, The British journal of dermatology.
[21] R. Atit,et al. Dermal fibroblast in cutaneous development and healing , 2018, Wiley interdisciplinary reviews. Developmental biology.
[22] M. Kirchin,et al. Non‐clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance®) to neonatal and juvenile rats , 2018, Regulatory toxicology and pharmacology : RTP.
[23] E. Gianolio,et al. The Issue of Gadolinium Retained in Tissues: Insights on the Role of Metal Complex Stability by Comparing Metal Uptake in Murine Tissues Upon the Concomitant Administration of Lanthanum- and Gadolinium-Diethylentriamminopentaacetate , 2017, Investigative radiology.
[24] Tyler J. Fraum,et al. Gadolinium‐based contrast agents: A comprehensive risk assessment , 2017, Journal of magnetic resonance imaging : JMRI.
[25] M. Kirchin,et al. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats , 2017, Journal of magnetic resonance imaging : JMRI.
[26] R. Semelka,et al. Gadolinium deposition disease: Initial description of a disease that has been around for a while. , 2016, Magnetic resonance imaging.
[27] R. Semelka,et al. Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases , 2016, Investigative radiology.
[28] R. Semelka,et al. Self-reported gadolinium toxicity: A survey of patients with chronic symptoms. , 2016, Magnetic resonance imaging.
[29] A. Hatamochi,et al. Effects of Gadodiamide on cell proliferation and collagen production in cultured human dermal fibroblasts , 2016, Archives of Dermatological Research.
[30] D. Hippe,et al. Macrocyclic and Other Non–Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function , 2016, Investigative radiology.
[31] K. Maravilla,et al. High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function , 2016, Investigative radiology.
[32] R. Brodell,et al. Gadolinium-associated plaques: a new, distinctive clinical entity. , 2015, JAMA dermatology.
[33] J. Barnes,et al. Type of MRI contrast, tissue gadolinium, and fibrosis. , 2014, American journal of physiology. Renal physiology.
[34] S. Jimenez,et al. Induction of a type I interferon signature in normal human monocytes by gadolinium‐based contrast agents: comparison of linear and macrocyclic agents , 2014, Clinical and experimental immunology.
[35] M. Rehman,et al. Stimulation of Fibroblast Proliferation by Insoluble Gadolinium Salts , 2012, Biological Trace Element Research.
[36] S. MacNeil,et al. Gadolinium Contrast Agent Associated Stimulation of Human Fibroblast Collagen Production , 2011, Investigative radiology.
[37] J. Varani,et al. Fibroblast Response to Lanthanoid Metal Ion Stimulation: Potential Contribution to Fibrotic Tissue Injury , 2011, Biological Trace Element Research.
[38] J. Varani,et al. Fibroblast Response to Gadolinium: Role for Platelet-Derived Growth Factor Receptor , 2010, Investigative radiology.
[39] R. Swartz,et al. Responses of Human Skin in Organ Culture and Human Skin Fibroblasts to a Gadolinium-Based MRI Contrast Agent: Comparison of Skin From Patients With End-Stage Renal Disease and Skin From Healthy Subjects , 2010, Investigative radiology.
[40] J. Quinn,et al. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. , 2010, Radiology.
[41] T. Steger-Hartmann,et al. A Review of Preclinical Safety Data for Magnevist (Gadopentetate Dimeglumine) in the Context of Nephrogenic Systemic Fibrosis , 2010, Investigative radiology.
[42] Rakesh Sharma. Gadolinium toxicity: epidermis thickness measurement by magnetic resonance imaging at 500 MHz , 2010, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.
[43] S. Jimenez,et al. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis , 2010, Annals of the rheumatic diseases.
[44] R. Swartz,et al. Collagenolytic Activity Is Suppressed in Organ-Cultured Human Skin Exposed to a Gadolinium-Based MRI Contrast Agent , 2010, Investigative radiology.
[45] R. Swartz,et al. Regulation of Collagen Turnover in Human Skin Fibroblasts Exposed to a Gadolinium-Based Contrast Agent , 2009, Investigative radiology.
[46] R. Swartz,et al. Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts , 2009, Investigative radiology.
[47] W. High,et al. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. , 2008, Journal of the American Academy of Dermatology.
[48] J. L. Abraham,et al. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. , 2008, Journal of the American Academy of Dermatology.
[49] T. Frenzel,et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.
[50] M. Edward,et al. Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis , 2008, The Journal of pathology.
[51] C. Robic,et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.
[52] R. Semelka,et al. Physicians with self-diagnosed gadolinium deposition disease: a case series , 2021, Radiologia brasileira.
[53] C. Mallio,et al. Impact of Brain Irradiation, Chemotherapy, and Presence of Primary Brain Tumors on Changes in Signal Intensity after Exposure to Gadolinium-based Contrast Agents. , 2019, Radiology.
[54] T. Moyer,et al. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. , 2011, Journal of the American Academy of Dermatology.
[55] B. Thiers. Quantification of gadolinium in nephrogenic systemic fibrosis: Re-examination of a reported cohort with analysis of clinical factors , 2009 .
[56] S. Cowper,et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[57] S. Cowper,et al. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.